Related Experiment Video
Updated: Sep 23, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosis
Richard J Gumina1, David A Foley, Ayalew Tefferi
1Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Abstract:
Polycythemia vera is a myeloproliferative disorder characterized by increased red cell mass and frequently complicated by venous and arterial thrombosis. The mechanism underlying the increased incidence of thrombotic events remains illusive. Presented in this report are a case of a 77-year-old man diagnosed with polycythemia vera and a review of the current literature on the mechanisms underlying the increased incidence of thrombotic events in polycythemia vera.
Insights
Polycythemia vera, a blood disorder, increases clot risk. This report reviews a case and literature to explore the elusive mechanisms behind thrombosis in polycythemia vera patients.
Area of Science:
- Hematology
- Oncology
- Vascular Medicine
Background:
- Polycythemia vera is a myeloproliferative neoplasm (MPN) defined by excessive red blood cell production.
- Increased red cell mass in polycythemia vera is associated with a high risk of thrombotic complications.
- The precise mechanisms driving thrombosis in polycythemia vera are not fully understood.
Observation:
- This report details a case of a 77-year-old male diagnosed with polycythemia vera.
- The patient's presentation and clinical course are described.
- Literature review focused on identifying potential thrombotic mechanisms.
Findings:
- Polycythemia vera involves complex interactions contributing to hyperviscosity and endothelial dysfunction.
- Abnormal platelet function and inflammatory mediators play a role in thrombogenesis.
- Genetic mutations, such as JAK2 V617F, are implicated in disease pathogenesis and thrombotic risk.
Implications:
- Understanding these mechanisms is crucial for developing targeted anti-thrombotic therapies.
- Improved risk stratification may lead to personalized treatment strategies for polycythemia vera.
- Further research into the pathophysiology of polycythemia vera can reduce morbidity and mortality from thrombosis.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Cirrhosis II: Pathophysiology

